{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:58:35Z","timestamp":1772164715399,"version":"3.50.1"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>To assess the impact of HCV eradication on the outcomes of cirrhotic patients treated curatively for incidental hepatocellular carcinoma (HCC) detected during surveillance program. Data were collected on 1,323 French patients with compensated biopsy-proven HCV cirrhosis recruited in 35 centers (ANRS CO12 CirVir cohort). Sustained virologic responses (SVR) and the occurrence of HCC were recorded prospectively. During a median follow-up of 68.3 months, 218 patients developed HCC, 126 of whom underwent a curative procedure as first-line therapy (ablation = 95, resection = 31). The HCC BCLC stage was 0\/A in 97.5% of patients; 74 (58.7%) never achieved SVR. During a median follow-up of 26.0 months after HCC treatment, 59 (46.8%) experienced HCC recurrence. SVR was not associated with a recurrence, whether considering final SVR status [HR = 0.77; 95% confidence interval (95% CI), 0.43\u20131.39; P = 0.39] or its time to achievement (prior to\/after HCC occurrence; global P = 0.28). During the same timeframe, 46 patients with HCC (36.5%) died (liver failure: 41.9%, HCC progression: 37.2%, extrahepatic causes: 20.9%). Under multivariate analysis, SVR was associated with improved survival [HR = 0.21; 95% CI, 0.08\u20130.52; P = 0.001]. Survival benefit was explained by a lower incidence of liver decompensation and higher rates of sequential HCC re-treatment. Direct antiviral intake was not associated with a higher risk of HCC recurrence, but with improved survival (HR = 0.23; 95% CI, 0.06\u20130.83; P = 0.024). HCV eradication in primary or secondary prevention optimizes HCC management through preservation of liver function and improves survival, whatever the regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Prevention Relevance:<\/jats:title>\n                    <jats:p>Liver failure is a competing risk of death in patients with HCC eligible for curative procedures. HCV eradication does not decrease risk of HCC recurrence in the first two years, but enables sequential curative HCC treatments through preservation of liver function. Direct-acting antiviral agent intake is not associated with HCC recurrence and improves survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1940-6207.capr-20-0465","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:05:20Z","timestamp":1613736320000},"page":"581-592","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management"],"prefix":"10.1158","volume":"14","author":[{"given":"Pierre","family":"Nahon","sequence":"first","affiliation":[{"name":"1Service d'H\u00e9patologie, H\u00f4pital Avicenne, AP-HP, Bobigny, France."},{"name":"2Universit\u00e9 Paris 13, Sorbonne Paris Cit\u00e9, \u201cEquipe labellis\u00e9e Ligue Contre le Cancer\u201d, Saint-Denis, France."},{"name":"3Inserm, UMR-1162, \u201cG\u00e9nomique fonctionnelle des tumeurs solides\u201d, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Layese","sequence":"additional","affiliation":[{"name":"4D\u00e9partement de Sant\u00e9 Publique, H\u00f4pital Henri Mondor, AP-HP and Universit\u00e9 Paris-Est, A-TVB DHU, CEpiA (Clinical Epidemiology and Ageing) Unit EA7376, UPEC, Cr\u00e9teil, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3061-1422","authenticated-orcid":false,"given":"Carole","family":"Cagnot","sequence":"additional","affiliation":[{"name":"5Unit for Basic and Clinical Research on Viral Hepatitis, ANRS (France REcherche Nord et sud Sida-HIV H\u00e9patites-FRENSH), Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"6Service d'H\u00e9patologie, H\u00f4pital Beaujon, AP-HP and University Paris Diderot, Sorbonne Paris Cit\u00e9, CRI, UMR 1149, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Guyader","sequence":"additional","affiliation":[{"name":"7Service d'H\u00e9patologie, CHU Pontchaillou, Rennes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"8D\u00e9partement d'H\u00e9patologie, H\u00f4pital Cochin, AP-HP, Paris, France;"},{"name":"9Inserm UMS20 et U1223, Institut Pasteur, Universit\u00e9 Paris Descartes, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges-Philippe","family":"Pageaux","sequence":"additional","affiliation":[{"name":"10Service d'H\u00e9patologie, H\u00f4pital Saint Eloi, Montpellier, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"De L\u00e9dinghen","sequence":"additional","affiliation":[{"name":"11Service d'H\u00e9patologie, H\u00f4pital Haut-L\u00e9v\u00eaque, Bordeaux, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Ouzan","sequence":"additional","affiliation":[{"name":"12Service d'H\u00e9patologie, Institut Arnaud Tzanck, St Laurent du Var, Nice, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[{"name":"13Service d'H\u00e9patologie et Universit\u00e9 de Lyon, Hospices Civils de Lyon, Lyon, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Audureau","sequence":"additional","affiliation":[{"name":"4D\u00e9partement de Sant\u00e9 Publique, H\u00f4pital Henri Mondor, AP-HP and Universit\u00e9 Paris-Est, A-TVB DHU, CEpiA (Clinical Epidemiology and Ageing) Unit EA7376, UPEC, Cr\u00e9teil, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"2022060817192092700_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"2022060817192092700_bib4","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"2022060817192092700_bib5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"2022060817192092700_bib6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"2022060817192092700_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jvh.12096","article-title":"A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma","volume":"20","author":"Huang","year":"2013","journal-title":"J Viral Hepat"},{"key":"2022060817192092700_bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jhep.2009.12.041","article-title":"Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach","volume":"52","author":"Shen","year":"2010","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1078-0432.CCR-12-0928","article-title":"Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer","volume":"19","author":"Brownell","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022060817192092700_bib10","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis","volume":"44","author":"Mazzaferro","year":"2006","journal-title":"Hepatology"},{"key":"2022060817192092700_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1200\/JCO.2012.44.3234","article-title":"Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus","volume":"31","author":"Shindoh","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022060817192092700_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1053\/j.gastro.2019.03.027","article-title":"Can we move on from the discussion of direct antiviral agents and risk of hepatocellular carcinoma recurrence?","volume":"156","author":"Nault","year":"2019","journal-title":"Gastroenterology"},{"key":"2022060817192092700_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.27743","article-title":"Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)","volume":"62","author":"Trinchet","year":"2015","journal-title":"Hepatology"},{"key":"2022060817192092700_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.04.027","article-title":"Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study","volume":"155","author":"Costentin","year":"2018","journal-title":"Gastroenterology"},{"key":"2022060817192092700_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep.28702","article-title":"Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)","volume":"64","author":"Ganne-Carrie","year":"2016","journal-title":"Hepatology"},{"key":"2022060817192092700_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"2022060817192092700_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"2022060817192092700_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"2022060817192092700_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"European Association for the Study of the L. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","year":"2010","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib20","first-page":"289","article-title":"Report of the baveno VI consensus workshop","volume":"15","author":"Cardenas","year":"2016","journal-title":"Ann Hepatol"},{"key":"2022060817192092700_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-310275","article-title":"Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)","volume":"66","author":"Nahon","year":"2017","journal-title":"Gut"},{"key":"2022060817192092700_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on treatment of hepatitis C","volume":"2018","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","author":"ANRS Collaborative Study Group on Hepatocellular Carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts)","year":"2016","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.13452","article-title":"Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response","volume":"37","author":"Bruno","year":"2017","journal-title":"Liver Int"},{"key":"2022060817192092700_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/apt.13821","article-title":"Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon","volume":"45","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2022060817192092700_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"key":"2022060817192092700_bib31","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north american cohort study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"2022060817192092700_bib32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apt.15296","article-title":"The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis","volume":"50","author":"Mecci","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/14\/5\/581\/3099654\/581.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/14\/5\/581\/3099654\/581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T15:19:58Z","timestamp":1654701598000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/14\/5\/581\/666346\/HCV-Eradication-in-Primary-or-Secondary-Prevention"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,19]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-20-0465","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.22534138","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534135","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6547381.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534138.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534135.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534141","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6547381","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22534141.v1","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]}}}